Steele, Keith E.
Tan, Tze Heng
Korn, René
Dacosta, Karma
Brown, Charles
Kuziora, Michael
Zimmermann, Johannes
Laffin, Brian
Widmaier, Moritz
Rognoni, Lorenz
Cardenes, Ruben
Schneider, Katrin
Boutrin, Anmarie
Martin, Philip
Zha, Jiping
Wiestler, Tobias
Article History
Received: 27 November 2017
Accepted: 14 February 2018
First Online: 6 March 2018
Ethics approval and consent to participate
: The clinical study (NCT01693562) from which the data in this report were obtained was carried out in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. The study protocol, amendments, and participant informed consent document were approved by the appropriate institutional review boards.
: No individual data were used in this study.
: KES, KD, CB, MK, AB, and PM are employees of MedImmune and own stock and/or stock options in AstraZeneca. THT, RK, J. Zimmerman, BL, MW, LR, RC, KS, and TW are employees of Definiens AG. J. Zha is an employee of NGM Biopharmaceuticals and at the time of this study was an employee of MedImmune and owned stock and/or stock options in AstraZeneca.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.